StreetInsider.com News Articles

Form 4 Moderna, Inc. For: Jul 15 Filed by: Hoge Stephen

Thu, 16 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260716/26780299.html

Form 4 Moderna, Inc. For: Jul 15 Filed by: Hoge Stephen

Thu, 16 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260716/26780299.html

Moderna doses first patient in Phase 1 trial for mRNA-4200 cancer therapy

Thu, 16 Jul 2026 07:01:09 -0400

Moderna, Inc. (NASDAQ: MRNA) has dosed the first U.S. participant in a Phase 1 clinical trial evaluating mRNA-4200, an investigational tumor-targeted cancer antigen therapy, in patients with advanced or metastatic solid tumors, according to a company press release.

mRNA-4200 encodes for seven antigens shared across patients and tumor types and is designed to induce and expand T-cell responses against selected tumor targets. The company describes it as its third off-the-shelf cancer antigen therapy candidate.

The first dose was administered by Dr. William McKean, a clinical investigator at START Mountain Region in Salt Lake City, Utah, part of The START Center for Cancer

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

Thu, 16 Jul 2026 07:00:00 -0400

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first U.S. participant in its Phase 1 study evaluating mRNA-4200, a tumor-targeted cancer antigen therapy candidate, in patients with advanced or metastatic solid tumors. mRNA-4200 encodes for seven antigens commonly shared across patients and tumor types and is designed to help induce and expand T-cell responses against selected tumor targets.

"mRNA-4200 represents our third off-the-shelf cancer antigen therapy candidate and builds on our efforts to explore broad applicability across multiple cancer types," said David

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors

Thu, 16 Jul 2026 07:00:00 -0400

"mRNA-4200 represents our third off-the-shelf cancer antigen therapy candidate and builds on our efforts to explore broad applicability across multiple cancer types," said David

Form 144 Moderna, Inc. Filed by: Hoge Stephen

Wed, 15 Jul 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260715/26772431.html

Form 144 Moderna, Inc. Filed by: Hoge Stephen

Wed, 15 Jul 2026 10:22:00 -0400

si-local-file:///var/storage/secattach/20260715/26772431.html

Form 4 Moderna, Inc. For: Jul 08 Filed by: McDonnell Michael R.

Fri, 10 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260710/26757988.html

Form 4 Moderna, Inc. For: Jul 08 Filed by: McDonnell Michael R.

Fri, 10 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260710/26757988.html

Form 3 Moderna, Inc. For: Jul 08 Filed by: McDonnell Michael R.

Fri, 10 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260710/26757979.html

Form 3 Moderna, Inc. For: Jul 08 Filed by: McDonnell Michael R.

Fri, 10 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260710/26757979.html

JPMorgan analysts name top short ideas for third quarter 2026

Fri, 10 Jul 2026 11:12:30 -0400

Investing.com -- JPMorgan released its list of top short ideas for the third quarter of 2026, featuring selections from its highest-ranked U.S. equity research analysts across multiple sectors.

The list includes 24 companies spanning capital goods, consumer, energy, financials, healthcare, materials, media and telecom, and technology sectors. Each selection represents what the bank's analysts view as their most compelling structural and tactical short positions.

In the technology sector, Intel Corp (NASDAQ:INTC) received an underweight rating from analyst Harlan Sur, while Wix.com Ltd (NASDAQ:WIX) was rated underweight by Alexei Gogolev.